QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: jpet.107.124768v1 323/1/19    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Matsson, P. Articles by Artursson, P. Search for Related Content PubMed PubMed Citation Articles by Matsson, P. Articles by Artursson, P.

METABOLISM, TRANSPORT, AND PHARMACOGENOMICS

A Global Drug Inhibition Pattern for the Human ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (ABCG2)

Pharmaceutical Screening and Informatics, Department of Pharmacy, Uppsala University, Sweden (P.M., G.E., G.A., C.A.S.B., U.N., P.A.); and AstraZeneca R&D, Södertälje, Sweden (U.N.)

In this article, we explore the entire structural space of registered drugs to obtain a global model for the inhibition of the drug efflux transporter breast cancer resistance protein (BCRP; ABCG2). For this purpose, the inhibitory effect of 123 structurally diverse drugs and drug-like compounds on mitoxantrone efflux was studied in Saos-2 cells transfected with human wild-type (Arg482) BCRP. The search for BCRP inhibitors throughout the drug-like chemical space resulted in the identification of 29 previously unknown inhibitors. The frequency of BCRP inhibition was 3 times higher for compounds reported to interact with other ATP-binding cassette (ABC) transporters than for compounds without reported ABC transporter affinity. An easily interpreted computational model capable of discriminating inhibitors from noninhibitors using only two molecular descriptors, octanol-water partition coefficient at pH 7.4 and molecular polarizability, was constructed. The discriminating power of this two-descriptor model was 93% for the training set and 79% for the test set, respectively. The results were supported by a global pharmacophore model and are in agreement with a two-step mechanism for the inhibition of BCRP, where both the drug's capacity to insert into the cell membrane and to interact with the inhibitory binding site of the transporter are important.

Address correspondence to: Dr. Per Artursson, Pharmaceutical Screening and Informatics, Department of Pharmacy, Uppsala University, P.O. Box 580, SE-751 23 Uppsala, Sweden. E-mail: Per.Artursson{at}farmaci.uu.se

This article has been cited by other articles:

				P. A. Pham, C. J. L. la Porte, L. S. Lee, R. van Heeswijk, J. P. Sabo, M. M. Elgadi, P. J. Piliero, P. Barditch-Crovo, E. Fuchs, C. Flexner, et al. Differential Effects of Tipranavir plus Ritonavir on Atorvastatin or Rosuvastatin Pharmacokinetics in Healthy Volunteers Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4385 - 4392. [Abstract] [Full Text] [PDF]

				N. Giri, S. Agarwal, N. Shaik, G. Pan, Y. Chen, and W. F. Elmquist Substrate-Dependent Breast Cancer Resistance Protein (Bcrp1/Abcg2)-Mediated Interactions: Consideration of Multiple Binding Sites in in Vitro Assay Design Drug Metab. Dispos., March 1, 2009; 37(3): 560 - 570. [Abstract] [Full Text] [PDF]